| NCT03366337 |
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX |
https://ClinicalTrials.gov/show/NCT03366337 |
Completed |
Reata Pharmaceuticals, Inc. |
2019-01-02 |
| NCT03342742 |
Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney Disease |
https://ClinicalTrials.gov/show/NCT03342742 |
Active, not recruiting |
University of Colorado, Denver |
2020-09-01 |
| NCT03273413 |
Statin Therapy in Patients With Early Stage ADPKD |
https://ClinicalTrials.gov/show/NCT03273413 |
Recruiting |
University of Colorado, Denver |
2021-12-31 |
| NCT03203642 |
Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD |
https://ClinicalTrials.gov/show/NCT03203642 |
Active, not recruiting |
Kadmon Corporation, LLC |
2022-01-31 |
| NCT03102632 |
A Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Kidney Disease |
https://ClinicalTrials.gov/show/NCT03102632 |
Recruiting |
The Rogosin Institute |
2021-12-31 |
| NCT03096080 |
A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD) |
https://ClinicalTrials.gov/show/NCT03096080 |
Completed |
Kadmon Corporation, LLC |
2019-09-30 |
| NCT02948179 |
Using Preimplantation Genetic Diagnosis in Autosomal Dominant Polycystic Kidney Disease Patients: a Multicenter Clinical Trial |
https://ClinicalTrials.gov/show/NCT02948179 |
Recruiting |
Shanghai Changzheng Hospital |
2020-09-30 |
| NCT02933268 |
High Water Intake in Polycystic Kidney Disease |
https://ClinicalTrials.gov/show/NCT02933268 |
Completed |
Cambridge University Hospitals NHS Foundation Trust |
2018-03-31 |
| NCT02903511 |
Feasibility Study of Metformin Therapy in ADPKD |
https://ClinicalTrials.gov/show/NCT02903511 |
Active, not recruiting |
University of Colorado, Denver |
2020-10-31 |
| NCT02776241 |
Effect of Water Intake and Water Restriction on Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease |
https://ClinicalTrials.gov/show/NCT02776241 |
Completed |
Rigshospitalet, Denmark |
2017-01-31 |
| NCT02729662 |
Efficacy of Tolvaptan on ADPKD Patients |
https://ClinicalTrials.gov/show/NCT02729662 |
Active, not recruiting |
Kyorin University |
2020-08-31 |
| NCT02697617 |
Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease |
https://ClinicalTrials.gov/show/NCT02697617 |
Active, not recruiting |
Indiana University |
2019-10-31 |
| NCT02558595 |
Pilot Study of Niacinamide in Polycystic Kidney Disease (NIAC-PKD2) |
https://ClinicalTrials.gov/show/NCT02558595 |
Completed |
University of Kansas Medical Center |
2017-12-18 |
| NCT02527863 |
Effect of the Aquaretic Tolvaptan on Nitric Oxide System |
https://ClinicalTrials.gov/show/NCT02527863 |
Completed |
Regional Hospital Holstebro |
2016-08-31 |
| NCT02494141 |
Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD |
https://ClinicalTrials.gov/show/NCT02494141 |
Active, not recruiting |
University of Colorado, Denver |
2020-12-31 |
| NCT02251275 |
Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease |
https://ClinicalTrials.gov/show/NCT02251275 |
Completed |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2018-11-09 |
| NCT02225860 |
Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney Disease |
https://ClinicalTrials.gov/show/NCT02225860 |
Completed |
Tufts Medical Center |
2016-02-29 |
| NCT02166489 |
Mesenchymal Stem Cells Transplantation in Patients With Chronic Renal Failure Due to Polycystic Kidney Disease |
https://ClinicalTrials.gov/show/NCT02166489 |
Completed |
Royan Institute |
2015-12-31 |
| NCT02160145 |
Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease |
https://ClinicalTrials.gov/show/NCT02160145 |
Completed |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2017-04-18 |
| NCT02140814 |
Uncontrolled, Open Label, Pilot and Feasibility Study of Niacinamide in Polycystic Kidney Disease |
https://ClinicalTrials.gov/show/NCT02140814 |
Completed |
University of Kansas Medical Center |
2016-02-29 |
| NCT02134899 |
The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients |
https://ClinicalTrials.gov/show/NCT02134899 |
Completed |
Assistance Publique - Hôpitaux de Paris |
2017-11-11 |
| NCT02127437 |
Lanreotide In Polycystic Kidney Disease Study |
https://ClinicalTrials.gov/show/NCT02127437 |
Completed |
Assistance Publique - Hôpitaux de Paris |
2019-07-31 |
| NCT02119052 |
Effects of Somatostatin on Liver in ADPKD |
https://ClinicalTrials.gov/show/NCT02119052 |
Completed |
Federico II University |
2013-09-30 |
| NCT02119013 |
Effects of Somatostatin on ADPKD Heart |
https://ClinicalTrials.gov/show/NCT02119013 |
Completed |
Federico II University |
2013-09-30 |
| NCT02112136 |
Clinical and Molecular Description of PKD1 and PKD2 Mutation Negative Carriers in ADPKD |
https://ClinicalTrials.gov/show/NCT02112136 |
Recruiting |
University Hospital, Brest |
2020-12-12 |
| NCT01280721 |
A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan] |
https://ClinicalTrials.gov/show/NCT01280721 |
Completed |
Otsuka Pharmaceutical Co., Ltd. |
2014-08-31 |
| NCT02055079 |
Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease |
https://ClinicalTrials.gov/show/NCT02055079 |
Recruiting |
Medical University of Vienna |
2019-04-30 |
| NCT01885559 |
HALT Progression of Polycystic Kidney Disease Study B |
https://ClinicalTrials.gov/show/NCT01885559 |
Completed |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
2014-06-30 |
| NCT01853553 |
Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
https://ClinicalTrials.gov/show/NCT01853553 |
Completed |
University of Colorado, Denver |
2017-01-31 |
| NCT01810614 |
A New Diet for Patients With Autosomal Dominant Polycystic Disease (ADPKD) |
https://ClinicalTrials.gov/show/NCT01810614 |
Completed |
University of Kansas Medical Center |
2014-11-30 |
| NCT01670110 |
Pasireotide LAR in Severe Polycystic Liver Disease |
https://ClinicalTrials.gov/show/NCT01670110 |
Completed |
Mayo Clinic |
2018-09-30 |
| NCT01632605 |
The Vienna RAP Pilot Study |
https://ClinicalTrials.gov/show/NCT01632605 |
Completed |
Medical University of Vienna |
2012-04-30 |
| NCT01559363 |
A Safety, Pharmacokinetic and Dose-Escalation Study of KD019 (Tesevatinib) in Subjects With ADPKD |
https://ClinicalTrials.gov/show/NCT01559363 |
Completed |
Kadmon Corporation, LLC |
2019-02-08 |
| NCT01451827 |
8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
https://ClinicalTrials.gov/show/NCT01451827 |
Completed |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2013-07-31 |
| NCT01377246 |
Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency |
https://ClinicalTrials.gov/show/NCT01377246 |
Completed |
Mario Negri Institute for Pharmacological Research |
2017-10-18 |
| NCT01336972 |
Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
https://ClinicalTrials.gov/show/NCT01336972 |
Completed |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2011-11-30 |
| NCT04363554 |
The Kidneys Ability to Concentrate and Dilute Urine in Patients With Autosomal Dominant Polycystic Kidney Disease |
https://ClinicalTrials.gov/show/NCT04363554 |
Completed |
Regional Hospital Holstebro |
2020-04-20 |
| NCT04284657 |
Pravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease |
https://ClinicalTrials.gov/show/NCT04284657 |
Recruiting |
University of Southern California |
2020-12-31 |
| NCT03949894 |
Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease |
https://ClinicalTrials.gov/show/NCT03949894 |
Recruiting |
Korea Otsuka Pharmaceutical Co., Ltd. |
2022-06-30 |
| NCT03918447 |
A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON |
https://ClinicalTrials.gov/show/NCT03918447 |
Recruiting |
Reata Pharmaceuticals, Inc. |
2023-03-31 |
| NCT03858439 |
Dietary Intervention in ADPKD on Tolvaptan |
https://ClinicalTrials.gov/show/NCT03858439 |
Recruiting |
McMaster University |
2020-09-30 |
| NCT03803124 |
Effect of Tolvaptan on Renal Plasma Flow (RPF) and Glomerular Filtration Rate (GFR) in ADPKD |
https://ClinicalTrials.gov/show/NCT03803124 |
Completed |
Regional Hospital Holstebro |
2017-12-15 |
| NCT03687554 |
Effect of Venglustat in Patients With Renal Impairment |
https://ClinicalTrials.gov/show/NCT03687554 |
Completed |
Sanofi |
2019-02-27 |
| NCT03596957 |
Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease |
https://ClinicalTrials.gov/show/NCT03596957 |
Recruiting |
Nordsjaellands Hospital |
2019-06-30 |
| NCT03541447 |
Tolvaptan-Octreotide LAR Combination in ADPKD |
https://ClinicalTrials.gov/show/NCT03541447 |
Recruiting |
Mario Negri Institute for Pharmacological Research |
2020-09-30 |
| NCT03487913 |
The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease |
https://ClinicalTrials.gov/show/NCT03487913 |
Completed |
Palladio Biosciences |
2019-12-02 |
| NCT02656017 |
Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease |
https://ClinicalTrials.gov/show/NCT02656017 |
Active, not recruiting |
University of Pittsburgh |
2020-12-30 |
| NCT03423810 |
Assessing a Doseâ€Response Relationship of Hydralazine and Its Effects on DNA Methyltransferase 1 in Polycystic Kidney Disease Patients |
https://ClinicalTrials.gov/show/NCT03423810 |
Completed |
University of Kansas Medical Center |
2020-01-30 |
| NCT01233869 |
Bosutinib For Autosomal Dominant Polycystic Kidney Disease |
https://ClinicalTrials.gov/show/NCT01233869 |
Completed |
Pfizer |
2014-07-31 |
| NCT01214421 |
Open-Label Tolvaptan Study in Subjects With ADPKD |
https://ClinicalTrials.gov/show/NCT01214421 |
Completed |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2016-02-29 |
| NCT01210560 |
Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD |
https://ClinicalTrials.gov/show/NCT01210560 |
Completed |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2011-06-30 |
| NCT01022424 |
A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002] |
https://ClinicalTrials.gov/show/NCT01022424 |
Completed |
Otsuka Pharmaceutical Co., Ltd. |
2014-07-31 |
| NCT00841568 |
A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001] |
https://ClinicalTrials.gov/show/NCT00841568 |
Completed |
Otsuka Pharmaceutical Co., Ltd. |
2010-11-30 |
| NCT03717181 |
Lixivaptan in a Single Subject With Intractable Pain Due to Polycystic Kidney Disease |
https://ClinicalTrials.gov/show/NCT03717181 |
Enrolling by invitation |
Palladio Biosciences |
2020-12-31 |
| NCT02021110 |
Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease |
https://ClinicalTrials.gov/show/NCT02021110 |
Completed |
Radboud University |
2015-10-31 |
| NCT03523728 |
A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients |
https://ClinicalTrials.gov/show/NCT03523728 |
Recruiting |
Sanofi |
2023-10-31 |
| NCT02964273 |
Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease) |
https://ClinicalTrials.gov/show/NCT02964273 |
Active, not recruiting |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2019-12-02 |
| NCT00784030 |
High Water Intake to Slow Progression of Polycystic Kidney Disease |
https://ClinicalTrials.gov/show/NCT00784030 |
Completed |
NYU Langone Health |
2009-05-31 |
| NCT00759369 |
Water as Therapy in Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
https://ClinicalTrials.gov/show/NCT00759369 |
Completed |
University of Kansas Medical Center |
2009-07-31 |
| NCT00598377 |
Adrenal Functions in Autosomal Dominant Polycystic Kidney Disease |
https://ClinicalTrials.gov/show/NCT00598377 |
Completed |
Istanbul University |
2007-09-30 |
| NCT00571909 |
Autosomal Dominant Polycystic Kidney Disease (ADPKD) Pain Study |
https://ClinicalTrials.gov/show/NCT00571909 |
Completed |
Mayo Clinic |
2016-01-31 |
| NCT00565097 |
Lanreotide as Treatment of Polycystic Livers |
https://ClinicalTrials.gov/show/NCT00565097 |
Completed |
Radboud University |
NA |
| NCT00491517 |
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety |
https://ClinicalTrials.gov/show/NCT00491517 |
Completed |
Mario Negri Institute for Pharmacological Research |
2009-07-31 |
| NCT00456365 |
Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
https://ClinicalTrials.gov/show/NCT00456365 |
Completed |
University of Colorado, Denver |
2012-10-31 |
| NCT00428948 |
Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
https://ClinicalTrials.gov/show/NCT00428948 |
Completed |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2012-01-31 |
| NCT00426153 |
Octreotide in Severe Polycystic Liver Disease |
https://ClinicalTrials.gov/show/NCT00426153 |
Completed |
Mayo Clinic |
2008-10-31 |
| NCT00414440 |
Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease |
https://ClinicalTrials.gov/show/NCT00414440 |
Completed |
Novartis |
2013-10-31 |
| NCT00413777 |
Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
https://ClinicalTrials.gov/show/NCT00413777 |
Completed |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2010-06-30 |
| NCT00410007 |
The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Autosomal Dominant Polycystic Kidney Disease |
https://ClinicalTrials.gov/show/NCT00410007 |
Completed |
Regional Hospital Holstebro |
2010-10-31 |
| NCT00346918 |
Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
https://ClinicalTrials.gov/show/NCT00346918 |
Completed |
University of Zurich |
2010-01-31 |
| NCT00345137 |
Effects of Systemic NO-Inhibition on Renal Hemodynamics in Patiens With Polycystic Kidney Disease and Chronic Glomerulonephritis |
https://ClinicalTrials.gov/show/NCT00345137 |
Completed |
Regional Hospital Holstebro |
NA |
| NCT00309283 |
Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study |
https://ClinicalTrials.gov/show/NCT00309283 |
Completed |
Mario Negri Institute for Pharmacological Research |
2012-01-31 |
| NCT00286156 |
Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
https://ClinicalTrials.gov/show/NCT00286156 |
Completed |
The Cleveland Clinic |
2012-03-31 |
| NCT00283686 |
HALT Progression of Polycystic Kidney Disease Study A |
https://ClinicalTrials.gov/show/NCT00283686 |
Completed |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
2014-06-30 |